Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (106 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-07-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 13.1% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placeboneuropathicto assesspatientdouble
  Phrases that lowered it: subjects whoresponse toto investigateinvestigate theeffect of
• Phase: 1/2 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 8.8% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 32 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 73.9% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 37971 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor's past trials: 61 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) NCT06593600 · started 2024 · scored riskier than 46% of active trials completed
• A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa NCT00782340 · started 2008 · scored riskier than 48% of active trials completed
• Norepinephrine Transporter Blockade, Autonomic Failure (NETAF) NCT02784535 · started 2016 · scored riskier than 26% of active trials completed
• Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome NCT03182725 · started 2018 · scored riskier than 63% of active trials completed
• Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure NCT04095793 · started 2019 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.